XERIS BIOPHARMA HOLDINGS INC

XERSNASDAQ

🏆 #1848 by market capEarnings Nov 5US Equity

$8.39▲ $0.41 (+4.94%)

Market closed · at close

1h—

24h▲ 4.9%

7d▲ 3.3%

14d▲ 0.1%

30d▲ 2.9%

1y▲ 15.2%

🏦Market Cap

$1.45B

Small Cap

📈Revenue Growth (YoY)

+41.5%

High Growth

📊Gross Margin

85.9%

High

💵FCF Margin

15.1%

Healthy

⚖️P/S Ratio

4.4x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $8.36 – $8.46
52-Week Range: $5.25 – $10.08
Volume: $2.06B
Avg Volume: $2.75B
Shares Outstanding: 172.6M
Next Earnings: Oct 15, 2026

Fundamentals Snapshot

Annual Revenue: $292M
Last Q Revenue: $92M
P/E Ratio: 114.9
P/S Ratio: 4.4x
EPS (TTM): $0.06
Dividend Yield: —

Why Investors Own XERS

✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
✓Healthy economics — 79% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$292M▲ +58.2% YoY

Gross Margin (TTM)

79.4%▲ +4.2% YoY

Operating Income (TTM)

$64M▲ +58.2% YoY

Free Cash Flow (TTM)

$58M▲ +58.2% YoY

About XERIS BIOPHARMA HOLDINGS INC

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

🦦